UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.51 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 8.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 191,065 shares of the company’s stock after selling 17,119 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.15% of Apellis Pharmaceuticals worth $5,510,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in APLS. Assenagon Asset Management S.A. raised its holdings in shares of Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after acquiring an additional 1,409,707 shares during the last quarter. Fiera Capital Corp grew its position in Apellis Pharmaceuticals by 47.7% in the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after purchasing an additional 452,753 shares in the last quarter. AQR Capital Management LLC grew its position in Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after purchasing an additional 190,420 shares in the last quarter. Old West Investment Management LLC bought a new stake in Apellis Pharmaceuticals in the 3rd quarter worth about $2,953,000. Finally, Algert Global LLC grew its position in Apellis Pharmaceuticals by 137.8% in the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock worth $4,742,000 after purchasing an additional 71,650 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $34.64 on Wednesday. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $73.80. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock has a market capitalization of $4.31 billion, a PE ratio of -17.06 and a beta of 0.94. The company’s 50 day simple moving average is $29.34 and its two-hundred day simple moving average is $34.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same quarter last year, the business posted ($1.17) EPS. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Activity

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This trade represents a 27.01 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 6.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on APLS shares. Robert W. Baird reduced their price objective on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Bank of America reduced their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. JPMorgan Chase & Co. reduced their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. William Blair started coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They issued an “outperform” rating for the company. Finally, HC Wainwright reduced their target price on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $49.94.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).